Metastatic Castrate Resistant Prostate Cancer Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Metastatic Castrate Resistant Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 3

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled235 locationsNCT06551324
Recruiting
Phase 1Phase 2

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals188 enrolled18 locationsNCT07206056
Recruiting
Phase 1

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (CRPC)
ARTBIO Inc.80 enrolled3 locationsNCT07214961
Recruiting
Phase 1

TmPSMA-02 in mCRPC

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
University of Pennsylvania30 enrolled1 locationNCT06046040
Recruiting
Phase 1Phase 2

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Institute of Cancer Research, United Kingdom78 enrolled4 locationsNCT07002320
Recruiting
Phase 1

Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Jean-Mathieu Beauregard60 enrolled1 locationNCT06943495
Recruiting
Phase 2

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Metastatic Castrate Resistant Prostate CancerBARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2RAD51B, RAD51C, RAD51D, or RAD54L Mutations
VA Office of Research and Development100 enrolled18 locationsNCT04038502
Recruiting
Phase 1Phase 2

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

mCRPC (Metastatic Castration-resistant Prostate Cancer)Metastatic Castrate Resistant Prostate Cancer
Evopoint Biosciences Inc.307 enrolled2 locationsNCT06702995
Recruiting

Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial

Metastatic Castrate Resistant Prostate Cancer (mCRPC)Kidney DiseaseRadiation Nephropathy
Hannah Schaefer100 enrolled1 locationNCT06720532